Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:1/3/2008

ASHBURN, Va., Jan. 2 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the US) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. GENTAMICIN SURGICAL IMPLANT is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totalling over 7,500 patients documenting its safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures.

Following a pre-IND meeting with the FDA earlier this year, Innocoll will conduct two multi-centered phase 3 clinical trials in the US to support the planned New Drug Application (NDA); the first in cardiac surgery patients at higher risk of surgical site infection and the second, expected to start later this month, in patients undergoing open colorectal surgery, which is considered to be the category most prone to surgical site infection. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 29 Zeltiq Aesthetics, a science-based medical device company dedicated ... unwanted fat tissue, has announced the appointment of Gordie ... Mitch Levinson, the founder of Zeltiq Aesthetics, who served as ... a member of the Board of Directors since 2006. ...
... Misonix, Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... release fourth quarter and fiscal year ended June 30, ... Michael A. McManus, President and Chief Executive Officer ...
Cached Medicine Technology:Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... a person loses a large amount of blood the consequences ... have to be kept available in hospitals and blood banks. ... villages and conducting blood donation sessions in a laboratory bus. ... taken contain pathogens, including HIV, hepatitis and syphilis. As these ...
... 1 , Watch4net,s Testimonial , ... healthcare providers in terms of limited personnel and budget ... Health. An industry typically marked by growth is starting ... level executives are being tasked to run leaner organizations ...
... Two-thirds of women with psoriasis say the disease ... PORTLAND, Ore., Oct. 1 Women with psoriasis and ... suffer from the emotional and psychological effects of the ... Psoriasis Foundation today. , Psoriasis is the most prevalent ...
... ... for life science careers and information, unveiled the eleventh edition of the Biotech Beach™ ... ... resource for life science careers and information, unveiled the eleventh edition of the Biotech ...
... ... University Edwardsville School of Pharmacy has launched a new Web site: www.pharmacypainsummit.com , ... pharmacy. , ... IL (PRWEB) October 1, 2009 -- The Southern Illinois University Edwardsville School of ...
... Oct.1 issue of the journal Sleep shows that ... consistently report that their sleep is shorter and poorer. ... all of the subjective measures, including a 13.2 minute shorter ... (SOL), and a 4.2 percent lower sleep efficiency. When sleep ...
Cached Medicine News:Health News:Blood diagnosis -- chip-based and mobile 2Health News:Clarian Health Selects Watch4net for Performance Reporting and Automatic Analysis 2Health News:Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 2Health News:Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 3Health News:BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 2Health News:SIUE School of Pharmacy Launches Collaborative Site for Pain, Palliative Care Pharmacy 2Health News:SIUE School of Pharmacy Launches Collaborative Site for Pain, Palliative Care Pharmacy 3Health News:Study shows that elderly women sleep better than they think, men sleep worse 2
... a fully threaded 2.4 mm diameter titanium suture ... predrilling using either a powered handpiece or manually ... This implant is ideal for Bankart and SLAP ... with very high pull-out strengths. FASTak anchors are ...
... one step fixation of soft tissue to bone. ... cuff repair in one simple insertion maneuver. The ... of 5 mm and a small 2 mm ... hold a thin, bioabsorbable PLLA disc 5 mm ...
... Needles are ideal for arthroscopic suture passing ... are preloaded on one end of each ... As the anchor is being inserted, ensure ... tissue before removing the handle to ensure ...
... a 3 mm x 14 mm bioabsorbable threaded ... shoulder, knee, elbow and ankle. The exclusive braided ... of the anchor and provides superior resistance to ... unique eyelet design allows the attached suture to ...
Medicine Products: